All In Biotech

Investigational drug · Phase 2

Liso-cel

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lymphoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

33

Any phase or sponsor naming "Liso-cel"

First trial start

2025

Nov 6, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Liso-cel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Lymphoma

Approved drugs for the same conditions: Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Liso-cel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 147 on PubMed

Also in development for Lymphoma

  • ZG005Phase 311 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer

  • OSE2101Phase 32 trials

    OSE Immunotherapeutics · Patients With Non-Small Cell Lung Cancer, Solid Advanced Tumor, Lymphoma

  • GecacitinibPhase 24 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Lymphoma, Non-small Cell Lung Cancer, Advanced Solid Tumor

  • AZD3470Phase 22 trials

    AstraZeneca · Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma

  • COH04S1GEO-CM04S1, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1Phase 22 trials

    GeoVax, Inc. · COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia

  • ASTX660Phase 21 trial

    Taiho Oncology, Inc. · Solid Tumors, Lymphoma

  • BT02Phase 21 trial

    Biotroy Therapeutics · Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma

  • CTS3497Phase 21 trial

    CytosinLab Therapeutics Co., Ltd. · Solid Tumor, Lymphoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.